Loss of hepatitis B surface antigen in a real-life clinical cohort of patients with chronic hepatitis B virus infection

Liver International

Volumn 35, Issue 1, 2015, Pages 130-139

  Habersetzer, François ^a,b,c   Moenne Loccoz, Rémy ^a   Meyer, Nicolas ^b,d   Schvoerer, Evelyne ^b,c,d,e,f   Simo Noumbissie, Pauline ^a   Dritsas, Stavros ^a,g   Baumert, Thomas F ^a,b,c   Doffoël, Michel ^a,b,c  

^a HÔPITAL CIVIL   (France)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c INSERM   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e CHU NANCY BRABOIS   (France)

^f UNIVERSITÉ DE LORRAINE   (France)

^g UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

Author keywords

Antiviral therapy; Chronic active hepatitis; Chronic HBV infection; Inactive carrier state; Incidence and predictive factors of HBsAg loss; Real life clinical cohort

Indexed keywords

ALPHA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE ANALOG; PEGINTERFERON ALPHA; VIRUS DNA; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; CHILD; CHRONIC ACTIVE HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PROSPECTIVE STUDY; PROTEIN DEPLETION; TREATMENT DURATION; BLOOD; CLINICAL TRIAL; FRANCE; HEPATITIS B, CHRONIC; HETEROZYGOTE; KAPLAN MEIER METHOD; MIDDLE AGED; VERY ELDERLY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARRIER STATE; COHORT STUDIES; FEMALE; FRANCE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 84921060974     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12661     Document Type: Article

References (28)

1. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
2. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-85.
3. Sorrell MF, Belongia EA, Costa J, et al. National institutes of health consensus development conference statement: management of hepatitis B. Ann Intern Med 2009; 150: 104-10.
4. Chu CM, Liaw YF, Hepatitis B. surface antigen seroclearance during chronic HBV infection. Antivir Ther 2010; 15: 133-43.
5. Chan HLY, Wong GLH, Tse CH, Chan HY, Wong VWS. Viral determinants of hepatitis B surface antigen seroclearance in hepatitis B e antigen-negative chronic hepatitis B patients. J Infect Dis 2011; 204: 408-14.
6. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-68.
7. Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 2002; 123: 1848-56.
8. Manno M, Cammà C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756-63.
9. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45: 1187-92.
10. Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology 2010; 139: 474-82.
11. Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51: 1531-7.
12. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101: 297-303.
13. Buster EHCJ, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-67.
14. Hosaka T, Suzuki F, Kobayashi M, et al. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study. J Gastroenterol 2013; 48: 930-41.
15. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
16. Seto WK, Wong DKH, Fung J, et al. A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. Hepatology 2012; 56: 812-9.
17. Seto WK, Wong DKH, Fung J, et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology 2013; 58: 923-31.
18. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CAB, Janssen HLA. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis 2011; 204: 415-8.
19. Marcellin P, Lau GKK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
20. Lau GKK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
21. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
22. Wong DKH, Yuen MF, Ngai VWS, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006; 11: 909-16.
23. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-84.
24. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-8.
25. Levrero M, Pollicino T, Petersen J, et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009; 51: 581-92.
26. Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343: 1221-8.
27. Wu JF, Chen CH, Ni YH, et al. Toll-like receptor and hepatitis B virus clearance in chronic infected patients: a long-term prospective cohort study in Taiwan. J Infect Dis 2012; 206: 662-8.
28. Cheng HR, Liu CJ, Tseng TC, et al. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients. PLoS ONE 2013; 8: e53008.